Are you currently (or have you been) in a Clinical Trial?
Comments
-
Saulius, You are certainly right about how slow they are- I didn't see any updates on these trials out there for a year- is the problem the tumor microenvironment is too tough? For DF they aren't saying how durable the responses are, yet the phase 2 is fairly large trial, so they should be accumulating some numbers by now- also they are notable as the only Her2 antibody to be offered in combination with checkpoint inhibitors or chemo, but is that because they only get a decent PFS when the antibody is used in combination?
Meanwhile, newer antibodies are coming along all the time, some bind both natural killer and T cells and facilitate interaction with tumors:
0 -
Hello all,
Well, good grief…
Good news: TTX-MC138 might have a slot open for me. I need a ferrin and transferrin saturation test before we'll know, and they want to do Caris and Tempus panel on me as well. This is all WONDERFUL news, except…
I was consulting with another facility and gave a verbal agreement to a different trial—NUV 1511, a drug-drug conjugate. I did call the facility as soon as I got word of TTX and told them to put a hold on the slot and I'm looking at another trial. But this would be the second time I've done that to this poor doctor, and I feel horrible. I certainly don't want to burn a bridge there either, and…
the last I read about TTX, they were not yet at therapeutic doses. BUT this is the 3rd (and I believe final cohort of their Phase 1 trial) so the dose is now 3.2mg as opposed to .4mg and .8mg. That's a big jump, so perhaps it will be therapeutic now…and I feel like my liver is only going to get worse, and if I want to try this trial, I better do it now. Their Phase 2 won't open until Summer 2025, and I don't want to miss my opportunity.
So my choices are:
- NUV-1511: a drug-drug conjugate. She said they've had a patient on it for 5 months. It is keeping people stable but not regressing. The side effects are blood-related (I don't remember what she said, cytopenia or something) but they are managing it. They have slots available and can get me in in three weeks or so.
- TTX-MC138: the one I really want, but not sure it's at a therapeutic dose yet. But I don't want to lose an opportunity to be in the Phase 2 trial.
I'm probably going to go with TTX, but Dr. Cheedella is going to murder me in my sleep. :/
CBL
0 -
CBL: I’d go for the TTX; I think it’s very reasonable to hope that the 3rd-cohort-dose is therapeutic.
1 -
Thank you, @luce. I think I'd be crazy to pass it up, but I feel terrible about going back on my verbal agreement. I probably should get over it, because she probably is by now, haha.
0 -
Okay, here's the latest:
I qualify for TTX if my ferritin and transferrin levels are not too high. I looked up the symptoms and I don't have any, so I think I'll be okay. We will discuss a start date on Tuesday when I sign the end of treatment paperwork for Bria-IMT.
My RECIST score for progression last time was 25%, this time it was like 39% or something horrible I already blocked out. So overall from baseline the two they were measuring grew like 3 cm, and the other 43 lesions had 'mild growth.' Well as far as I'm concerned, mild growth of 43 little ones is still a hell of a lot!
I hope the TTX lives up to the hype. My math sucks, but I think there is a 400% increase from .8 to 3.24? That's cohort 2 vs. cohort 3, so if it's not therapeutic, it's at least better than I could've had. We shall see. I'll get all the deets on TTX (if I pass the tests) on Tuesday I believe.
As far as canceling the verbal agreement, my nurse said not to worry about it. It's the nature of the beast, and if the tables were turned, he'd understand and it happens all the time. So letting that go. (but still not canceling until I know if I'm guaranteed a spot in TTX)
That's it for this report. I'll update on Tuesday.
CBL
0 -
CBL, Any info on whether anyone has had a durable response on TTX?
0 -
The last thing I read is that there has been no response yet, but that was because they were not at therapeutic doses yet.
"Despite the fact that responses have not been observed yet, and some investors might be disappointed, H.C. Wainwright notes that the initial cohorts are likely below therapeutic dose levels. It is also highlighted that the study is still in the early stages of dose escalation with only three patients enrolled in each cohort."
So with the 400% increase in dose, I think I have a shot at it being therapeutic and hopefully fingers crossed it will work!
0 -
Cure-ious,
I'm off Enhertu effective yesterday, so need to make some big decisions. I've learned of another study at Univ Wisconsin Madison that my oncologist did not mention: NCT06157892. The drug is Disitamab Vedotin alone or with other anti-cancer drugs. It's related to Her2. I've now sent a message to my oncologist with questions. What do you know about this study or drug?
0
